The Centers for Disease Control and Prevention on Feb. 26 issued a safety advisory concerning a rabies treatment made by Talecris Biotherapeutics Inc. Three lots of the Rabies Immune Globulin do not permit certain dosages to be administered.
The agency said health care providers may continue to administer the pre-filled syringe by following revised directions for use packaged with the affected lots. For more information, see the CDC Health Advisory.
[ via AHA News Now ]
Comments